09/13/2025
Many of you are familiar with semaglutide, which has become a powerful and effective option for weight loss and metabolic health. But as many of you have experienced personally, getting insurance approval for it can be incredibly difficult — especially if you're not on insulin or don’t meet very specific medical criteria.
We've seen patients who truly need it struggle through denials, appeals, and delays. It often takes a lot of time, effort, and frustration to fight for access to a medication that can meaningfully improve your health. You're not alone in that fight — and we see how hard it is.
But there’s a bit of good news:
Wegovy (semaglutide 2.4 mg) , (also applies to Ozempic )has just been approved by the FDA for a new indication — treating metabolic dysfunction-associated steatohepatitis (MASH) in noncirrhotic patients with moderate to advanced liver fibrosis.
This is more than just a label change — it’s a step forward that may help open more doors for coverage and access to semaglutide, especially for patients with complex metabolic and liver-related conditions. It may also push insurance companies to rethink how and for whom this medication is made available.
We’ll continue to advocate for our patients and keep you informed as these changes evolve.
With care,
P. K. Garg MD
